Lupin Limited

Equities

LUPIN

INE326A01037

Pharmaceuticals

Market Closed - Bombay S.E. 06:00:56 2024-07-19 am EDT 5-day change 1st Jan Change
1,786 INR -1.65% Intraday chart for Lupin Limited -0.60% +35.02%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Lupin Sells US Commercial Women's Health Specialty Business to Evofem Biosciences MT
Lupin Gets Establishment Inspection Report from US FDA After Dabhasa Unit, Inspection MT
Evofem Bio.sciences, Inc. acquired Womens Health Specialty Business of Lupin Limited for $84 million. CI
INDIA STOCKS-IT leads Indian shares to record highs RE
India plans incentives for diabetes, obesity drug makers in 2026, government official says RE
Indian Equities Fall on Friday, Dragged Mainly by Banking Stocks MT
Lupin Loses Appeal Against EU Anti-Trust Fine MT
Lupin Appoints CEO for Subsidiary Lupin Manufacturing Solutions MT
Lupin Gets Zero Observations from US FDA After Nagpur, India Unit Inspection MT
Lupin Arm Acquires Two Brands from Sanofi in Europe and Canada MT
India's pharma export sales to grow faster this year, trade body says RE
Indian drugmakers to see FY25 revenue boost in key US market, says India Ratings and Research RE
Lupin Gets Six Observations from US FDA After Somerset Unit Inspection MT
U.S. FDA Concludes a Pre Approval Inspection at Lupin's Somerset, New Jersey Manufacturing Facility CI
Lupin Relaunches Mirabegron ER Tablets in US MT
Nomura Adjusts Lupin’s Price Target to INR1,952 From INR1,949, Keeps at Buy MT
Lupin Limited Announces Board Appointments CI
Jefferies Adjusts Lupin’s Price Target to INR1,535 From INR1,460 Keeps at Hold MT
Transcript : Lupin Limited, Q4 2024 Earnings Call, May 07, 2024
Lupin's Consolidated Profit Climbs in Fiscal Q4; Shares Dip 4% MT
Indian drugmaker Lupin misses quarterly profit estimates as costs rise RE
Lupin Limited Recommends Dividend for the Year Ended March 31, 2024 CI
Lupin Limited Reports Earnings Results for the Fourth Quarter Ended March 31, 2024 CI
Lupin Limited Reports Earnings Results for the Fourth Quarter and Full Year Ended March 31, 2024 CI
Lupin Limited Receives Approval from U.S. FDA for Travoprost Ophthalmic Solution USP CI
Chart Lupin Limited
More charts
Lupin Limited is a leading Indian pharmaceutical group. Its products are used to treat tuberculosis, diabetes, asthma, cardiovascular diseases, infections, etc. The group's activity is organized around 2 areas: - design and production of generic and brand-name formulations; - production of active pharmaceutical ingredients. At the end of March 2022, the group had 15 production sites India (12), the United States, Mexico and Brazil. Net sales break down geographically as follows: India (39.4%), the United States (34.1%) and other (26.5%).
Calendar
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
A
More Ratings
Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
34
Last Close Price
1,786 INR
Average target price
1,638 INR
Spread / Average Target
-8.28%
Consensus
  1. Stock Market
  2. Equities
  3. LUPIN Stock
  4. News Lupin Limited
  5. Lupin Arm Acquires Two Brands from Sanofi in Europe and Canada